Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial
Authors: He Min , Jiang Yi-Zhou , Gong Yue , Fan Lei , Liu Xi-Yu , Liu Yin , Tang Li-Chen , Mo Miao , Hou Yi-Feng , Di Gen-Hong , Liu Guang-Yu , Yu Ke-Da , Wu Jiong , Yan Xia , Zeng Xiao-Hua , Fu De-Yuan , Song Chuan-Gui , Zhuang Zhi-Gang , Wu Ke-Jin , Wang Jie , Wang Zhong-Hua , Shao Zhi-Ming 
Published: October 2024

Abstract

Objective
To evaluate the feasibility of using a multigene signature to tailor individualised adjuvant therapy for patients with operable triple negative breast cancer.

Design
Randomised, multicentre, open label, phase 3 trial.

Setting
7 cancer centres in China between 3 January 2016 and 17 July 2023.

Participants
Female patients aged 18-70 years with early triple negative breast cancer after definitive surgery.

Interventions
After risk stratification using the integrated signature, patients at high risk were randomised (1:1) to receive an intensive adjuvant treatment comprising four cycles of docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin (arm A; n=166) or a standard treatment of four cycles of epirubicin and cyclophosphamide followed by four cycles of docetaxel (arm B; n=170). Patients at low risk received the same adjuvant chemotherapy as arm B (arm C; n=168).

Main outcome measures
The primary endpoint was disease-free survival in the intention-to-treat analysis for arm A versus arm B. Secondary endpoints included disease-free survival for arm C versus arm B, recurrence-free survival, overall survival, and safety.

Results

Among the 504 enrolled patients, 498 received study treatment. At a median follow-up of 45.1 months, the three year disease-free survival rate was 90.9% for patients in arm A and 80.6% for patients in arm B (hazard ratio 0.51, 95% confidence interval (CI) 0.28 to 0.95; P=0.03). The three year recurrence-free survival rate was 92.6% in arm A and 83.2% in arm B (hazard ratio 0.50, 95% CI 0.25 to 0.98; P=0.04). The three year overall survival rate was 98.2% in arm A and 91.3% in arm B (hazard ratio 0.58, 95% CI 0.22 to 1.54; P=0.27). The rates of disease-free survival (three year disease-free survival 90.1%
v
80.6%; hazard ratio 0.57, 95% CI 0.33 to 0.98; P=0.04), recurrence-free survival (three year recurrence-free survival 94.5%
v
83.2%; 0.42, 0.22 to 0.81; P=0.007), and overall survival (three year overall survival 100%
v
91.3%; 0.14, 0.03 to 0.61; P=0.002) were significantly higher in patients in arm C than in those in arm B with the same chemotherapy regimen. The incidence of grade 3-4 treatment related adverse events were 64% (105/163), 51% (86/169), and 54% (90/166) for arms A, B, and C, respectively. No treatment related deaths occurred.

Conclusions
The multigene signature showed potential for tailoring adjuvant chemotherapy for patients with operable triple negative breast cancer. Intensive regimens incorporating gemcitabine and cisplatin into anthracycline/taxane based therapy significantly improved disease-free survival with manageable toxicity.

Trial registration

ClinicalTrials.gov
NCT02641847
.